news

CUPERTINO, Calif., Oct. 31 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2001. The company’s net loss attributable to common stockholders for the three months ended September 30, 2001 was $8.9 million or 19 cents per share compared to $6.0 million, or 62 cents per share, […]

CUPERTINO, Calif., Oct 25, 2001 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced yesterday research results showing in animal models that new blood vessels are formed and that blood flow to an ischemic heart can be restored following targeted delivery of fibroblast growth factor to the heart. Dr. Randolph M. Johnson, DURECT’s Vice President

CUPERTINO, Calif., Oct 16, 2001 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present on technologies for targeted drug delivery at the Techvest 3rd Annual Conference on Tissue Repair, Replacement and Regeneration (TR3). The conference is scheduled for October 23rd and 24th at the Hilton New York. Randolph M. Johnson,

CUPERTINO, Calif., Oct 15, 2001 /PRNewswire via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, October 31, 2001 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive

CUPERTINO, Calif., Sept. 24 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Judy Magruder has been promoted to the position of Senior Vice President of Regulatory and Development and Tai Wah Chan, Ph.D. has been promoted to Vice President of Pharmaceutical Research and Development effective September 1, 2001. “We are pleased to announce the

CUPERTINO, Calif., Sept. 5 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today the results of its Phase II clinical trial for its lead product Chronogesic(TM), a 3-month continuous infusion subcutaneous implant for the treatment of chronic pain. The clinical trial was conducted at 9 clinical sites in the United States and enrolled 66 adult patients

CUPERTINO, Calif., Aug 24, 2001 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) press release regarding Chronogesic(TM) Phase II clinical trial data, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, September 5, 2001 at 8:30 a.m. EDT with Jim Brown, President and Chief

CUPERTINO, Calif., July 30 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2001. The company’s net loss attributable to common stockholders for the three months ended June 30, 2001 was $7.0 million or 15 cents per share (excluding a one-time, non-cash charge) compared to $5.2 million,

CUPERTINO, Calif., Jul 19, 2001 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, July 30, 2001 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive Officer, Tom

CUPERTINO, Calif., Jul 6, 2001 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that its Board of Directors adopted a Stockholder Rights Plan. The Rights Plan is designed to protect and maximize the value of stockholders’ interest in DURECT Corporation, to enable all DURECT stockholders to realize the full value of their investment and to